National Research Co. (NASDAQ:NRC) Director Donald M. Berwick sold 9,035 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $63.01, for a total transaction of $569,295.35.

Shares of NASDAQ NRC opened at $61.73 on Friday. The firm’s 50-day moving average price is $49.80 and its 200-day moving average price is $36.28. National Research Co. has a 1-year low of $35.58 and a 1-year high of $68.86. The firm has a market capitalization of $1.53 billion, a P/E ratio of 59.36 and a beta of 0.82. The company has a current ratio of 0.62, a quick ratio of 0.62 and a debt-to-equity ratio of 1.24.

National Research (NASDAQ:NRC) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.03. National Research had a net margin of 24.59% and a return on equity of 124.11%. The firm had revenue of $31.41 million for the quarter, compared to analyst estimates of $30.26 million.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Monday, September 30th will be issued a dividend of $0.19 per share. The ex-dividend date is Friday, September 27th. This represents a $0.76 annualized dividend and a dividend yield of 1.23%. National Research’s dividend payout ratio is currently 73.08%.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Quantamental Technologies LLC raised its holdings in shares of National Research by 125.2% during the second quarter. Quantamental Technologies LLC now owns 743 shares of the company’s stock valued at $43,000 after purchasing an additional 413 shares during the period. Bank of Montreal Can acquired a new position in shares of National Research during the second quarter valued at about $59,000. Advisor Group Inc. raised its holdings in shares of National Research by 17.8% during the second quarter. Advisor Group Inc. now owns 2,263 shares of the company’s stock valued at $131,000 after purchasing an additional 342 shares during the period. BNP Paribas Arbitrage SA raised its holdings in shares of National Research by 10,395.5% during the first quarter. BNP Paribas Arbitrage SA now owns 2,309 shares of the company’s stock valued at $89,000 after purchasing an additional 2,287 shares during the period. Finally, Aperio Group LLC acquired a new position in shares of National Research during the second quarter valued at about $176,000. Hedge funds and other institutional investors own 36.03% of the company’s stock.

About National Research

National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Company’s portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement.

Featured Story: Cost of Capital Explained

Insider Buying and Selling by Quarter for National Research (NASDAQ:NRC)

Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.